利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

233 条记录 (耗时 0.037 秒)

    Radiotracer Derivatives Of Trimethoprim For Diagnostic Imaging
    4.
    发明申请
    Radiotracer Derivatives Of Trimethoprim For Diagnostic Imaging 有权

    公开(公告)号：US20210138093A1

    公开(公告)日：2021-05-13

    申请号：US17099511

    申请日：2020-11-16

    申请人： The Trustees of the University of Pennsylvania

    发明人： Mark Sellmyer ,  Robert H. Mach ,  David A. Mankoff ,  Iljung Lee

    IPC分类号： A61K51/04 ,  A61K31/395 ,  A61K31/495 ,  A61K49/00 ,  C07D239/49 ,  C07D403/12 ,  A61K47/54 ,  A61K31/505

    摘要： The present invention provides radiolabeled trimethoprim which are useful in imaging tests such as PET scans. The compounds show robust bacterial uptake in vitro and identify infections from inflammation or tumor when administered to a subject. The compounds show rapid and sensitive detection of Ec DHFR containing tumors from control tumors and background tissue. In one aspect, a compound having the structure of formula (I) is provided or a pharmaceutically acceptable salt or prodrug thereof, wherein R is defined herein. Also provided are compositions containing these compounds, positron emission tomography reporter probe comprising these compounds, and methods of imaging a bacterial infection, tracking or monitoring bacteria, distinguishing a bacterial infection from inflammation or tumor, monitoring genetically fused protein expression, and monitoring genetically engineered cells in clinical scenarios such as immunotherapy for cancer treatment.

    Carboxylic acid compounds
    8.
    发明授权
    Carboxylic acid compounds 有权

    公开(公告)号：US10562861B2

    公开(公告)日：2020-02-18

    申请号：US16167974

    申请日：2018-10-23

    申请人： Sumitomo Dainippon Pharma Co., Ltd.

    发明人： Seiji Hori ,  Futoshi Hasegawa ,  Daisuke Urabe ,  Hirotaka Kurebayashi

    IPC分类号： C07D239/49 ,  C07D239/48 ,  C07D403/12 ,  C07D403/10 ,  C07D239/47 ,  A61K31/505 ,  A61K31/506

    摘要： The present disclosure concerns at least one entity chosen from compounds of Formula (I) and pharmaceutically acceptable salts thereof: wherein the variable groups X, R1, R2, R3 m, n and p are as defined herein. The present disclosure also relates to methods for the preparation of at least one such entity, and intermediates useful in the preparation thereof, to pharmaceutical compositions containing at least one such entity, to the use of at least one such entity in the preparation of medicaments, and to the use of at least one such entity in the treatment of conditions such as, for example, allergic diseases, autoimmune diseases, viral diseases, and cancer.